Sling Therapeutics, Inc.

ACTIVE

455 E Eisenhower Pkwy Ste 300, 密歇根州沃什特瑙县, 密歇根州, United Statesslingtx.comHolding1–10 employeesEstablished: 2020-01-01

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2020

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 2

33.3%

Phase 3

16.7%

Trial Status Distribution

Active, not recruiting

33.3%

Completed

16.7%

Recruiting

50.0%

Clinical Trials

Trials sponsored by this organization (6)

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Phase 3

Recruiting

interventional

Aug 2026130 participants

Phase I trial; HMR code: 24-003

Phase 1

Active, not recruiting

interventional

Aug 202420 participants

Study to Evaluate the Safety and Efficacy of Linsitinib in Patients with Active, Moderate to Severe Thyroid Eye Disease

Phase 1

Active, not recruiting

interventional

Jun 202418 participants

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Phase 2

Recruiting

interventional

Oct 202375 participants

A Study to Evaluate Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

Phase 1

Recruiting

interventional

Apr 202375 participants

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Phase 2

Completed

interventional

Jul 202290 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations